Published in Nucleic Acids Res on February 27, 2008
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res (2008) 2.20
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res (2009) 1.98
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet (2014) 1.58
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Reproducibility: changing the policies and culture of cell line authentication. Nat Methods (2015) 1.43
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood (2011) 1.12
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res (2009) 0.99
Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. Nucleic Acids Res (2010) 0.98
SNP array profiling of mouse cell lines identifies their strains of origin and reveals cross-contamination and widespread aneuploidy. BMC Genomics (2014) 0.94
Development of SNP-based human identification system. Int J Legal Med (2010) 0.93
Development of a fingerprinting panel using medically relevant polymorphisms. BMC Med Genomics (2009) 0.89
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov (2017) 0.87
Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system. PLoS One (2015) 0.87
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget (2016) 0.81
Pitfalls in the detection of cholesterol in Huntington's disease models. PLoS Curr (2012) 0.80
Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samples. PLoS One (2014) 0.79
Evaluating information content of SNPs for sample-tagging in re-sequencing projects. Sci Rep (2015) 0.78
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget (2016) 0.78
Robust In-Silico identification of cancer cell lines based on next generation sequencing. Oncotarget (2017) 0.75
Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res (2016) 0.75
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet (2016) 0.75
A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. Oncotarget (2016) 0.75
A haplotype map of the human genome. Nature (2005) 105.70
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Informativeness of genetic markers for inference of ancestry. Am J Hum Genet (2003) 6.90
Genetics. Genomic research and human subject privacy. Science (2004) 6.56
Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A (1999) 5.63
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell (2003) 3.33
Developing a SNP panel for forensic identification of individuals. Forensic Sci Int (2005) 2.55
Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer (1999) 2.20
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des (1997) 1.89
Cell biology. Cases of mistaken identity. Science (2007) 1.79
Selection and use of SNP markers for animal identification and paternity analysis in U.S. beef cattle. Mamm Genome (2002) 1.79
Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J (2005) 1.78
Proportioning whole-genome single-nucleotide-polymorphism diversity for the identification of geographic population structure and genetic ancestry. Am J Hum Genet (2006) 1.76
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett (2006) 1.68
Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res (1995) 1.29
20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res (1995) 1.11
Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res (1997) 1.10
Widely used prostate carcinoma cell lines share common origins. Prostate (2001) 1.04
Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genet Cytogenet (2004) 1.03
Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes Cancer (2006) 0.99
Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet Cytogenet (2000) 0.89
Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat (2006) 0.87
The protective effect of metallothionein against lipid peroxidation caused by retinoic acid in human breast cancer cells. J Pharmacol Exp Ther (1997) 0.80
LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. Clin Exp Metastasis (2004) 0.80
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (2004) 6.78
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48